Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019
First Line Treatment for CLL - Ibrutinib Plus Obinutuzumab, Ibrutinib Plus/Minus Rituximab
Login to view comments.
Click here to Login
Malignant Hematology